MYELOPEROXIDASE BREAKTHOUGH LEE BIOSOLUTIONS

Published: Apr 14th, 2006

The New England Journal of Medicine published an article on October 23 that explains how a single initial measurement of plasma myeloperoxidase
(mpo), which is found in white blood cells, independently predicts the early risk of cardiovascular disease. In addition, myeloperoxidase levels can predict the risk of major adverse cardiac events such as ischemia, myocardial infarction, and congestive heart failure, as well as heart cancer, Multiple Sclerosis, and other ailments.

This information was made possible by a study completed by the Cleveland Clinic Foundation. Their study consisted of 604 sequential emergency room patients that were experiencing chest pain. The results of the study show that the patients with the highest levels of myeloperoxidase face a significantly higher risk of a cardiac crisis within two months.

Myeloperoxidase is provided by Lee Biosolutions, a St. Louis based manufacturer that is committed to the continued development, manufacture, and marketing of enzymes and related fine chemicals for the diagnostic and Life Science industries.

Lee Biosolutions provides proteins, enzymes and other materials to research facilities around the country that develop tests in order to advance the healthcare industry. By providing solutions on demand, Lee Biosolutions has become the preferred source for myeloperoxidase. They sell myeloperoxidase in any quantity needed, package it for the client\'s unique need, and produce it to meet the client\'s schedule. Clients can purchase just the enzyme needed or the entire product. Lee Bio has been producing myeloperoxidase for many years, and holds the best knowledge, capabilities and capacity for customization to provide myeloperoxidase to meet any application.

Experts are eager to pursue the vast array of possibilities for myeloperoxidase as outlined in the Cleveland Clinic study, calling the study a major breakthrough that could revolutionize testing for and prevention of many ailments, including cardiovascular disease.

Doctors believe that myeloperoxidase
blood tests would first be used in emergency rooms to distinguish patients who are genuinely at risk of a cardiac emergency from the millions who have chest pain from other causes. Eventually, the test may be offered in doctors' offices as part of a battery of blood tests capable of identifying those who have heart disease but aren\'t aware. Doctors will be able to diagnose an imminent heart attack sooner and act quickly to prevent it.

For more information about myeloperoxidase ,contact:

Lee Biosolutions, Inc
2924 Mary Ave
St. Louis, MO 63144
Tel:314-968-1091
www.leebio.com